1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
ADC ratio of abnormal to normal brain parenchyma
Time of Imaging with Reference to Symptom OnsetPatients No.: Age/Sex
1:49/F2:41/F3:55/M
Early period, days 0–2 (n = 2 patients)59% (day 1)77% (day 2)
Middle period, days 3–30 (n = 3 patients)83% (day 13)100% (day 22)114% (day 12)
89% (day 26)
Late period, days 31+ (n = 2 patients)137% (day 47)132% (day 45)
115% (day 98)
  • Note:—ADC indicates apparent diffusion coefficient.